Measurable residual disease shows strong potential as an early indicator of survival in patients with AML

Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable indicator of long-term outcomes for patients with acute myeloid…

Continue Reading

News Source: medicalxpress.com